SAL0132
/ Shenzhen Salubris
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 10, 2026
SUSTAINED REDUCTIONS IN ANGIOTENSINOGEN AND BLOOD PRESSURE WITH AN RNA INTERFERENCE THERAPEUTIC: INTERIM RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF GW906 IN CHINA
(ACC 2026)
- "Abstract is embargoed at this time."
First-in-human • P1 data • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1